15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Eton Pharmaceuticals Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $31.00 to $60.00, a moderate spread. The average target of $45.75 sits 2% below the current $46.64. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.31 next quarter toward $2.14 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Eton Pharmaceuticals Inc.
As of Jul, 4 of 4 firms rate ETON a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ETON EPS & revenue forecast
EPS · NEXT QUARTER
$0.31
Range $0.31 – $0.31 · 2 analysts · +675% YoY
Next period, 2 analysts expect Eton Pharmaceuticals Inc to earn $0.31 a share (range $0.31 – $0.31), versus $0.04 a year earlier. Full-year consensus is $1.04, growing to $2.14 the year after.
REVENUE · NEXT QUARTER
$31.8M
Range $28.8M – $33.0M · 2 analysts · +42% YoY
Revenue is expected to reach $31.8M (range $28.8M – $33.0M), +41.5% year-over-year. Full-year consensus is $121.1M, rising to $184.4M next year.
Top analysts covering Eton Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ETON.
#1
Chase Knickerbocker
Craig-Hallum · Rank #25
Buy
$35.00-25.0% to target
Overall win rate
58%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$57.00+22.2% to target
Overall win rate
37%
+ Follow
#3
ME
Madison El-Saadi
B. Riley Securities
Buy
$31.00-33.5% to target
Coverage
—
+ Follow
#4
GN
Gary Nachman
Canaccord Genuity
Buy
$60.00+28.6% to target
Coverage
—
+ Follow
ETON stock forecast FAQ
What is ETON's average 12-month price target?+
The 4 analysts with a live target average $45.75 for Eton Pharmaceuticals Inc over the next 12 months, ranging from a $60.00 high to a $31.00 low.
Is ETON stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ETON?+
The Street-high target is $60.00 (Canaccord Genuity), and the Street-low is $31.00 (B. Riley Securities). The average of all 4 active targets is $45.75.
How many Wall Street analysts cover ETON?+
4 analysts have an active rating on Eton Pharmaceuticals Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ETON?+
Among analysts who currently cover ETON, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #25). Their current call is Buy with a $35.00 target.
What is Eton Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.31 per share (range $0.31 – $0.31) across 2 analysts. Full-year EPS is projected at $1.04, rising to $2.14 the following year.
How much revenue is Eton Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $31.8M (range $28.8M – $33.0M). Full-year revenue is projected at $121.1M, growing to $184.4M next year.
Have analysts been upgrading or downgrading ETON lately?+
As of Jul, 4 of 4 firms rate ETON a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ETON calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
